Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Oxytocin for Prevention of Postpartum Depression
NCT02505984Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2016
- Primary completion
- May 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in postpartum depression (PPD) and anxiety disorder comparing Oxytocin with Placebo (2 arms). Primary endpoint: Treatment Effect on Mother-infant Bonding at 2 months. Started Jan 2016; status: completed.
02
Drugs
oxytocin
03
Conditions
postpartum depression (PPD)anxiety disorder
Beyond the preview
Go deeper on NCT02505984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02505984.